347 related articles for article (PubMed ID: 34489967)
1. Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors.
Roulleaux Dugage M; Jones RL; Trent J; Champiat S; Dumont S
Front Immunol; 2021; 12():715727. PubMed ID: 34489967
[TBL] [Abstract][Full Text] [Related]
2. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
Front Immunol; 2021; 12():775761. PubMed ID: 34925348
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
[TBL] [Abstract][Full Text] [Related]
4. Current status of immunotherapy for gastrointestinal stromal tumor.
Tan Y; Trent JC; Wilky BA; Kerr DA; Rosenberg AE
Cancer Gene Ther; 2017 Mar; 24(3):130-133. PubMed ID: 28186088
[TBL] [Abstract][Full Text] [Related]
5. Latest advances in adult gastrointestinal stromal tumors.
Florou V; Wilky BA; Trent JC
Future Oncol; 2017 Oct; 13(24):2183-2193. PubMed ID: 28984483
[TBL] [Abstract][Full Text] [Related]
6. Role of immune microenvironment in gastrointestinal stromal tumours.
Blakely AM; Matoso A; Patil PA; Taliano R; Machan JT; Miner TJ; Lombardo KA; Resnick MB; Wang LJ
Histopathology; 2018 Feb; 72(3):405-413. PubMed ID: 28871595
[TBL] [Abstract][Full Text] [Related]
7. Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.
Ali Abuderman AW; M Aldakheel F
Cell Mol Biol (Noisy-le-grand); 2020 Dec; 66(8):26-32. PubMed ID: 34174973
[TBL] [Abstract][Full Text] [Related]
8. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
[TBL] [Abstract][Full Text] [Related]
9. Translating Knowledge About the Immune Microenvironment of Gastrointestinal Stromal Tumors into Effective Clinical Strategies.
Chantharasamee J; Adashek JJ; Wong K; Eckardt MA; Chmielowski B; Dry S; Eilber FC; Singh AS
Curr Treat Options Oncol; 2021 Jan; 22(1):9. PubMed ID: 33400014
[TBL] [Abstract][Full Text] [Related]
10. Is exon mutation analysis needed for adjuvant treatment of gastrointestinal stromal tumor?
Sendur MA; Ozdemir NY; Akinci MB; Uncu D; Zengin N; Aksoy S
World J Gastroenterol; 2013 Jan; 19(1):144-6. PubMed ID: 23326179
[TBL] [Abstract][Full Text] [Related]
11. Macrophages and CD8
Zhang JQ; Zeng S; Vitiello GA; Seifert AM; Medina BD; Beckman MJ; Loo JK; Santamaria-Barria J; Maltbaek JH; Param NJ; Moral JA; Zhao JN; Balachandran V; Rossi F; Antonescu CR; DeMatteo RP
Cancer Immunol Res; 2018 Apr; 6(4):434-447. PubMed ID: 29467128
[TBL] [Abstract][Full Text] [Related]
12. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.
Balachandran VP; Cavnar MJ; Zeng S; Bamboat ZM; Ocuin LM; Obaid H; Sorenson EC; Popow R; Ariyan C; Rossi F; Besmer P; Guo T; Antonescu CR; Taguchi T; Yuan J; Wolchok JD; Allison JP; DeMatteo RP
Nat Med; 2011 Aug; 17(9):1094-100. PubMed ID: 21873989
[TBL] [Abstract][Full Text] [Related]
13. The immune system and gastrointestinal stromal tumor: a wealth of opportunities.
Tan Y; Garcia-Buitrago MT; Trent JC; Rosenberg AE
Curr Opin Oncol; 2015 Jul; 27(4):338-42. PubMed ID: 26049274
[TBL] [Abstract][Full Text] [Related]
14. Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation.
Indio V; Ravegnini G; Astolfi A; Urbini M; Saponara M; De Leo A; Gruppioni E; Tarantino G; Angelini S; Pession A; Pantaleo MA; Nannini M
Front Immunol; 2020; 11():851. PubMed ID: 32670260
[TBL] [Abstract][Full Text] [Related]
15. [Targeted therapy combined with immunotherapy in gastrointestinal stromal tumor: a new era of hope and challenges].
Zhao W; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):966-971. PubMed ID: 28900984
[TBL] [Abstract][Full Text] [Related]
16. Molecular research directions in the management of gastrointestinal stromal tumors.
Tarn C; Godwin AK
Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers and novel therapeutic targets in gastrointestinal stromal tumors (GISTs).
Campanella NC; de Oliveira AT; Scapulatempo-Neto C; Guimarães DP; Reis RM
Recent Pat Anticancer Drug Discov; 2013 Sep; 8(3):288-97. PubMed ID: 23198834
[TBL] [Abstract][Full Text] [Related]
18. KIT oncogene inhibition drives intratumoral macrophage M2 polarization.
Cavnar MJ; Zeng S; Kim TS; Sorenson EC; Ocuin LM; Balachandran VP; Seifert AM; Greer JB; Popow R; Crawley MH; Cohen NA; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
J Exp Med; 2013 Dec; 210(13):2873-86. PubMed ID: 24323358
[TBL] [Abstract][Full Text] [Related]
19. Immune Cell Infiltration and the Expression of PD-1 and PD-L1 in Primary PDGFRA-Mutant Gastrointestinal Stromal Tumors.
Sun X; Sun J; Yuan W; Gao X; Fu M; Xue A; Li H; Shu P; Fang Y; Hou Y; Shen K; Sun Y; Qin J; Qin X
J Gastrointest Surg; 2021 Aug; 25(8):2091-2100. PubMed ID: 33169322
[TBL] [Abstract][Full Text] [Related]
20. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.
Chi P; Chen Y; Zhang L; Guo X; Wongvipat J; Shamu T; Fletcher JA; Dewell S; Maki RG; Zheng D; Antonescu CR; Allis CD; Sawyers CL
Nature; 2010 Oct; 467(7317):849-53. PubMed ID: 20927104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
